We are live on ! Find out more
LEXX icon

Lexaria Bioscience
LEXX

17 hedge funds and large institutions have $1.85M invested in Lexaria Bioscience in 2023 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 3 increasing their positions, 3 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more first-time investments, than exits

New positions opened: 2 | Existing positions closed: 1

10% more capital invested

Capital invested by funds: $1.67M → $1.85M (+$173K)

6% more funds holding

Funds holding: 16 → 17 (+1)

0% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 3

0.3% less ownership

Funds ownership: 11.72% → 11.41% (-0.3%)

Holders
17
Holders Change
+1
Holders Change %
+6.25%
% of All Funds
0.27%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
3
Reduced
3
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
+$5.98K
2
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$3.76K
3
FFA
Farther Finance Advisors
California
+$473
4
Wells Fargo
Wells Fargo
California
+$97
5
Toronto Dominion Bank
Toronto Dominion Bank
Ontario, Canada
+$37

Top Sellers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
-$45.8K
2
CC
Centiva Capital
New York
-$2.85K
3
UBS Group
UBS Group
Switzerland
-$2.73K
4
TRCT
Tower Research Capital (TRC)
New York
-$2.66K
Name Holding Trade Value Shares
Change 		Change in
Stake
ICM
1
Invenomic Capital Management
Massachusetts
$1.29M – – –
Susquehanna International Group
2
Susquehanna International Group
Pennsylvania
$183K +$3.76K +1,321 +2%
Geode Capital Management
3
Geode Capital Management
Massachusetts
$133K – – –
Vanguard Group
4
Vanguard Group
Pennsylvania
$90.7K – – –
Dimensional Fund Advisors
5
Dimensional Fund Advisors
Texas
$41.5K – – –
Renaissance Technologies
6
Renaissance Technologies
New York
$37K +$5.98K +2,100 +18%
CC
7
Centiva Capital
New York
$32.8K -$2.85K -1,000 -8%
UBS Group
8
UBS Group
Switzerland
$12.6K -$2.73K -957 -17%
TRCT
9
Tower Research Capital (TRC)
New York
$11K -$2.66K -935 -19%
1832 Asset Management
10
1832 Asset Management
Ontario, Canada
$7.3K – – –
Osaic Holdings
11
Osaic Holdings
Arizona
$5.56K – – –
Wells Fargo
12
Wells Fargo
California
$2.91K +$97 +34 +3%
APC
13
Aspire Private Capital
North Carolina
$1.09K – – –
Royal Bank of Canada
14
Royal Bank of Canada
Ontario, Canada
$1K – – –
FFA
15
Farther Finance Advisors
California
$452 +$473 +166 New
GCM
16
Gables Capital Management
Florida
$35 – – –
Citadel Advisors
17
Citadel Advisors
Florida
– -$45.8K -18,674 Closed
Toronto Dominion Bank
18
Toronto Dominion Bank
Ontario, Canada
– +$37 +13 New

LEXX Hedge Fund Activity: Q1 2023 in Review

17 of the 6,276 institutional investors tracked by Wall St. Rank reported a position in Lexaria Bioscience (LEXX) for Q1 2023, worth a combined $1.85M — up 10% from $1.67M a quarter earlier.

Buyers outnumbered sellers: 2 funds opened new LEXX positions and 1 closed out — a net gain of 1 holder — while 3 added to existing stakes and 3 trimmed.

The largest buyer was Renaissance Technologies, adding an estimated $5.98K. The largest seller was Citadel Advisors, exiting entirely with an estimated $45.8K sold.

  • 17 institutional investors held Lexaria Bioscience (LEXX) as of Q1 2023, up from 16 in Q4 2022.
  • Funds reported $1.85M of Lexaria Bioscience stock for Q1 2023, up 10% quarter-over-quarter.
  • 2 funds opened new Lexaria Bioscience positions in Q1 2023 and 1 closed out, a net change of +1 holder.
  • The largest Lexaria Bioscience buyer in Q1 2023 was Renaissance Technologies, an estimated $5.98K added.
  • The largest Lexaria Bioscience seller in Q1 2023 was Citadel Advisors, an estimated $45.8K sold.

Based on aggregated 13F filings for Q1 2023.